Personalizing Medicine through AI

Our Approach

Focused on Changing Breast Cancer Outcomes

PreciseDx is dedicated to supporting more personalized and precise treatments for breast cancer.

 

On average, every two minutes a woman is diagnosed with breast cancer in the United States.

About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.

About PreciseDx

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.

Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists

Better Data. Better Outcomes.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.

  • Patients
  • Providers
  • Payers
  • BioPharma

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Patients

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

Providers

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

Payers

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

BioPharma

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

“PreciseDx has an opportunity to improve the quality for all patients through our digital platform. The level of patient-specific detail we can provide to oncologists and pathologists is unmatched, and our ability to provide this as a digital service means that we are not bound by location.”

Jack Zeineh, PreciseDx

“PreciseDx has an opportunity to improve the quality for all patients through our digital platform. The level of patient-specific detail we can provide to oncologists and pathologists is unmatched, and our ability to provide this as a digital service means that we are not bound by location.”

Featured Resources & Media

Media Coverage
June 15, 2022
Inside Precision Medicine
How Digital Pathology is Advancing Biomarker Identification & Drug Discovery
Media Coverage
May 6, 2022
Neurology Live
The Future of Digital Neuropathology and the Role of AI: John F. Crary, MD, PhD; Gerardo Fernandez, MD
Media Coverage
April 26, 2022
FierceHealthcare
Mount Sinai spinout developed algorithm that accurately diagnoses early-stage Parkinson’s, per new study

Interested in Learning More?

Contact Us